跳至主要内容
临床试验/NCT02465125
NCT02465125已完成2 期

The Transfusion Triggers in Vascular Surgery Trial: Two Different Transfusion Triggers for Postoperative Haemoglobin Separation and Adherence to Transfusion Strategies in Vascular Surgery: a Randomised Clinical Feasibility Trial

Naestved Hospital2 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2015年7月15日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
58
试验地点
2
主要终点
Mean Post-operative hemoglobin (longitudinal outcome)

研究概览

简要总结

BACKGROUND

  • Vascular surgical patients often receive red blood cell (RBC) transfusions in the peri-operative period
  • RBC transfusion may lead to improved outcome but on the other hand the intervention may be harmful
  • Danish Health and Medicines Authority recommends transfusion of RBC at hemoglobin below 5 mmol/L while local clinical guidelines recommend transfusion of RBC to maintain hemoglobin levels above 6 mmol/L
  • A large randomized clinical trial is needed to evaluate the efficacy and safety of RBC transfusion in patients undergoing vascular surgery.
  • A trial examining the effect of RBC transfusion on tissue oxygenation is used to test the trial-design and feasibility for a trial evaluating post-operative mortality and morbidity.

详细描述

DESIGN Single-center, randomized, open-label trial including vascular surgical patients for peri-operative red blood cell (RBC) transfusion.

If the patient drops out of the trial, either at his/her own request or due to withdrawal from active therapy, the patient will be followed up in the intention-to-treat analyses.

PROTOCOL SUSPENSION

The patient can temporarily be suspended from the protocol in the following circumstances, if the clinician in charge finds indication for blood transfusions not adhering to the planned transfusion threshold:

  • Uncontrollable bleeding, defined as loss of surgical hemostasis resulting in overt or imminent hemodynamic instability with insufficient tissue oxygenation and increasing lactate production OR
  • Hypotension unresponsive to fluid replacement OR
  • Decompensated heart failure OR
  • Stroke, extremity- and intestinal ischaemia

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients for planned open repair of the abdominal aorta or infrainguinal arterial bypass
  • Hemoglobin < 6 mmol/L

排除标准

  • Documented wish against transfusion
  • Previous serious adverse reaction with blood products
  • Unable to understand the benefits and risks of testing
  • Previous participation in trial

研究组 & 干预措施

Low transfusion trigger

Active Comparator

Intervention group. Low or restrictive transfusion trigger: hemoglobin < 5 mmol/L (approx. 8 g/dl or a hematocrit of 25%) This trigger is what is recommended by the Danish Health and Medicines Authority for stable patients with chronic heart disease.

干预措施: red blood cell transfusion (Biological)

High transfusion trigger

Active Comparator

Control group. High or liberal transfusion trigger: hemoglobin < 6 mmol/L (approx. 10 g/dl or a hematocrit of 30%) This trigger reflects the practice among Danish vascular anesthesiologists and correspond to the transfusion trigger recommended by the European society for vascular surgery

干预措施: red blood cell transfusion (Biological)

结局指标

主要结局

Mean Post-operative hemoglobin (longitudinal outcome)

时间窗: Day 0 - 15

Day 0 is the hemoglobin measured upon arrival at the recovery room or at the intensive care unit depending on what level of care the patient needs after surgery.

次要结局

  • Explorative Outcomes(90 days after operation)
  • Recruitment rate with 95% confidence interval(Day -1 (day before operation))
  • Protocol suspension(30 days after operation)
  • Units of red blood cells transfused (count data)(30 days after operation)
  • Protocol adherence(30 days after operation)
  • Changes in coagulation competence measured by rotational thromboelastometry (ROTEM)(An expected average time frame of 3 hours)
  • Intraoperative tissue oxygenation(Participants will be monitored during their stay at the operation theatre, an expected average of 3 hours)
  • Severe adverse events(30 days after operation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anders Møller

Resident

Slagelse Hospital

研究点 (2)

Loading locations...

相似试验